Newsletter

086450 - Dong Kook Pharmaceutical Co., Ltd.

086450 Summary
Biopharma
Stock Price & Overview
₩21,600 -200 (-0.92%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩21,600  ≈ US$15  ·  Market cap ₩1.0tn (≈ $698m)

086450 Dividend Summary

Dividend per share, FY2025₩200Yield at last close0.93%
Yield reported by the company (FY-end)1.14%Payout ratio (consolidated)13.7%
Total cash dividends₩9.0bnEarnings per share₩1,487
Consecutive years paid (on file)12DPS growth, 5-year CAGR+2.1%
Dividend decisions filed in 20260
Per-share and payout figures are the company's own, from the dividend section of its DART annual report. 'Yield at last close' divides that per-share amount by the latest KRX close; the company-reported yield uses the fiscal-year-end price.

086450 Dividend History

Fiscal yearDPS (common)ChangeYield (FY-end)PayoutTotal cash ₩bnEPSDPS (preferred)
FY2025₩2000.0%1.14%13.7%9.0₩1,487—
FY2024₩200+11.1%1.21%15.1%9.2₩1,382₩584
FY2023₩1800.0%1.14%17.6%8.3₩1,064₩519
FY2022₩1800.0%1.04%14.7%8.1₩1,203₩180
FY2021₩1800.0%0.83%15.2%8.0₩1,146₩180
FY2020₩180+12.5%0.63%13.9%8.0₩1,273₩180
FY2019₩160+53.8%0.90%12.1%7.2₩1,281—
FY2018₩1040.0%0.89%9.4%4.7₩1,068—
FY2017₩104+30.0%0.85%11.2%4.6₩901—
FY2016₩80+33.3%0.71%8.6%3.5₩925—
FY2015₩600.0%0.53%9.7%2.6₩624—
FY2014₩60—0.86%12.5%2.6₩478—
Annual totals per fiscal year, interim and year-end combined, as reported in the annual report filed the following March. A year-end dividend for FY2025 is paid in April 2026. Per-share figures from before a par-value split are restated to today's share count using the par-value ratio, so the series is comparable.

086450 Dividend Decisions (filings)

All filings »

No filings on file yet.

A Korean dividend arrives as two filings: the board's cash-dividend decision (amount, record date, payment date) and, for year-end dividends, a shareholder-register closing notice.

How Korean dividends work

  • Record date and amount. Traditionally the record date was the fiscal year-end (December 31) and the amount was only set at the board meeting and AGM in February–March, so investors bought before knowing the payout. Under the 2023 procedure reform, companies that amended their articles now fix the amount first and set the record date afterwards; many large caps have adopted this, others still use the year-end date.
  • Ex-dividend. KRX settles T+2, so a share goes ex-dividend one business day before the record date. Year-end dividends are paid within a month of the AGM that approves them, typically April.
  • Interim and quarterly dividends need a provision in the articles; a minority of large companies pay quarterly, most pay once a year.
  • Withholding tax. Korea withholds 22% (20% plus local tax) from non-resident holders by default; the Korea–US treaty lowers it to 15% (10% for a corporate holder of at least 10%), subject to your broker filing the treaty paperwork. Residents pay 15.4%.
  • Preferred shares (“우선주”) usually carry a slightly higher per-share dividend than common shares and no vote.

Similar to 086450

SymbolLast Price
127120JS Link₩33,600
+12.4%
475830Orum Therapeutics, Inc.₩55,900
+2.6%
195940HK inno.N Corporation₩42,050
+0.7%
003090Daewoong Co., Ltd.₩16,860
-2.0%
185750Chong Kun Dang Pharmaceutical Corp.₩68,000
-0.3%
115180Qurient Co., Ltd.₩23,050
+17.3%
476830Rznomics, Inc.₩28,200
+6.8%
003850Boryung Corporation₩9,040
+1.6%
950260Ingenia Therapeutics Inc.(reg.s)₩15,580
-1.5%
085660Chabiotech Co., Ltd.₩8,090
+2.1%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.